Serum levels of leptin, adiponectin and resistin in patients with ankylosing spondylitis: A systematic review and meta-analysis

Yang, Jiajia; Zhang, Xu; Ma, Yubo; Wu, Meng; Hu, Xingxing; Han, Renfang; Yuan, Yaping; Wang, Mengmeng; Chen, Mengya; Jiang, Shanqun; Tong, Jing-Jing; Xu, Shengqian; Xu, Jianhua; Shuai, Zongwen; Zou, Yanfeng; Pan, Faming

doi:10.1016/j.intimp.2017.09.029

Cited by 17 publications

(16 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22,23,25 Furthermore, no association was evident between leptin serum levels and radiological progression. 26–28 In ankylosing spondylitis (AS), most studies, including two recent meta-analyses, agree that leptin levels are comparable to those of healthy individuals 29–31 while some investigators have reported decreased leptin serum levels in male patients. 32 In contrast to what is observed in RA, leptin levels in AS do not seem to correlate with disease activity 33 and leptin levels at the time of the diagnosis offer protection for subsequent radiologic progression.…”

Section: Inflammatory Pathways In Obesity and Rheumatic Diseasesmentioning

confidence: 99%

Inflammation, obesity and rheumatic disease: common mechanistic links. A narrative review

Nikiphorou

Fragoulis

2018

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Obesity represents a rising global health concern, linked to significant social, psychological and physical burden to the individual affected, people around them and the society as a whole. Obesity has been described as a low-grade inflammatory condition, associated with increased production of pro-inflammatory mediators like tumor necrosis factor alpha or interleukin 6 and altered expression of adipokines. Adipokines, mainly produced by adipose tissue, have mixed pro- and anti-inflammatory properties. Obesity rarely exists on its own; instead, it tends to coexist with (often multiple) other comorbidities, including metabolic, cardiovascular, and rheumatic and musculoskeletal diseases (RMDs). In the case of RMDs, evidence is rapidly accumulating on common mechanistic pathways implicated in the inflammatory states seen between RMDs and obesity. Although there remain unanswered questions on the exact mechanisms of inflammation that link obesity to RMDs, what is becoming increasingly known is the association between obesity and adverse clinical outcomes in RMDs. This narrative review discusses insights into mechanisms of inflammation linking obesity and RMDs and evidence on the impact of obesity on treatment response and important disease outcomes. We highlight the importance of targeting obesity, a common and modifiable comorbidity, as part of the routine care of people with RMDs.

show abstract

Section: Inflammatory Pathways In Obesity and Rheumatic Diseasesmentioning

confidence: 99%

Inflammation, obesity and rheumatic disease: common mechanistic links. A narrative review

Nikiphorou

Fragoulis

2018

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

show abstract

“…Adipokines appear to drive metabolic alterations, pro-inflammatory as well as anti-inflammatory, and human resistin can stimulate the pro-inflammatory cytokines by NF-kappaB (NF-k B) pathway 25 . Resistin was extensively studied in rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis and osteoarthritis [26][27][28] . It can bind toll-like receptor 4 (TLR4) on human leukocytes and increase the producing of pro-inflammatory cytokines, such as interleukin(IL)-6, IL-12 and IL-1β, in turn, these cytokines also enhance resistin expression 29 .…”

Section: Discussionmentioning

confidence: 99%

Elevated serum levels of resistin in inflammatory bowel disease: a meta-analysis

Deng¹,

Chen²,

Xu³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

The findings of the prior studies investigating the resistin levels in Crohn's disease (CD) patients and ulcerative colitis (UC) patients are inconsistent. Hence we performed the meta-analysis to systematically evaluate the serum levels of resistin in CD and UC, as well as in healthy individuals. PubMed, Web of Science, Embase, Cochrane Library and Chinese National Knowledge Infrastructure (CNKI) (as of April 30, 2020) were searched to collect all relevant published articles. We calculated the pooled standard mean difference (SMD) and 95% confidence interval (CI) by R software. Eight articles including 438 CD patients and 358 controls, and 9 articles including 391 UC patients and 438 controls were enrolled. The results showed that resistin levels were significantly elevated in patients with CD (SMD = 1.76, 95% CI: 0.64 to 2.88, p = 0.002) and UC (SMD = 2.10, 95% CI: 1.03 to 3.17, p < 0.001) compared with healthy controls. Our findings indicate that the elevated levels of serum resistin were associated with CD and UC.

show abstract

“…Serum leptin correlated with measurements of disease activity (Bath ankylosing spondylitis disease activity index [BASDAI]) or acute phase reactants (CRP, IL-6) ( 69 ). A recent meta-analysis found no differences in serum leptin or serum adiponectin between AS and controls, while patients with AS had higher serum resistin levels ( 70 ). A second meta-analysis confirmed these results for serum leptin, indicating that there is no significant difference in plasma/serum leptin between patients and controls ( 71 ).…”

Section: Adipokines In Rheumatoid Arthritismentioning

confidence: 99%

Mini-Review: The Contribution of Adipokines to Joint Inflammation in Inflammatory Rheumatic Diseases

Toussirot

2020

Front. Endocrinol.

View full text Add to dashboard Cite

Inflammatory rheumatic diseases (IRD) are complex disorders characterized by chronic inflammation of the joints and related skeletal structures. The most common forms of IRD are rheumatoid arthritis (RA) and spondyloarthritis (SpA), including axial SpA (axSpA) and psoriatic arthritis (PsA). Obesity is a frequent comorbidity in RA and PsA, and to a lesser extend in axial SpA. The association between obesity and IRD may be explained by the release from fat tissue of several bioactive proteins, namely adipokines. Adipokines are involved in the regulation of various processes such as lipid or glucose metabolism, but also inflammation. Adipokines are interrelated with the immune system, with both innate and adaptive immune cell connections. Several adipokines with pro-inflammatory effects have been identified such as leptin, visfatin or resistin. Conversely, adiponectin and more specifically its low molecular weight isoform, is considered to have antiinflammatory properties. In this review, we discuss the contribution of adipokines to the joint inflammation of IRD, the relation they have with immune pathways of these diseases, their links with the structural impact on peripheral joints and/or axial skeleton, and also the influence they may have on the cardiometabolic risk of IRD.

show abstract

Serum levels of leptin, adiponectin and resistin in patients with ankylosing spondylitis: A systematic review and meta-analysis

Cited by 17 publications

References 64 publications

Inflammation, obesity and rheumatic disease: common mechanistic links. A narrative review

Inflammation, obesity and rheumatic disease: common mechanistic links. A narrative review

Elevated serum levels of resistin in inflammatory bowel disease: a meta-analysis

Mini-Review: The Contribution of Adipokines to Joint Inflammation in Inflammatory Rheumatic Diseases

Contact Info

Product

Resources

About